
Pharma Pulse 2/17/25: Strategies for Addressing Unmet Needs in Women’s Health, The Future of Personalized Medicine & more
The latest news for pharma industry insiders.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, shares how the development of technology will help bolster the pharma logistics industry.
Panelists discuss how menopause marks a significant life transition, characterized by hormonal decline, reproduction cessation, and unique physiological changes requiring medical and emotional support. Health care professionals guide women through life’s reproductive stages, providing comprehensive health care from menarche to post menopause, focusing on individualized prevention of symptom management, and holistic well-being across hormonal transitions.
Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.
Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available.
“When I got here, everybody said Teva is a generics company. I said, I don’t think it is. When I looked under the hood, I saw this innovation - some launched, some in the pipeline - and then I saw this world-class generics business. I said, this is a pharma company that does both.”
Our CEO, Richard Francis, sat down with
Richard emphasizes our organization’s commitment to innovation and sustainable growth, sharing a roadmap on where our organization is heading in 2025 and beyond.
Check out the full interview from Pharma Exec here:
#Tevapharm #PivottoGrowth #Innovation
Have news you want us to share in Pharma Pulse? Reach out to Editor
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





